Education
About Us
Working with TipRanks
Follow Us
Tyra Bioscience (TYRA)
NASDAQ:TYRA
TYRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.42 - $29.60
Previous CloseN/A
Volume80.11K
Average Volume (3M)192.03K
Market Cap
$720.58M
Enterprise Value$279.65M
Total Cash (Recent Filing)$296.27M
Total Debt (Recent Filing)$6.02M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Oct 30, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding53,297,140
10 Day Avg. Volume160,743
30 Day Avg. Volume192,031
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue563.82
Enterprise Value/Gross Profit-14.72K
Enterprise Value/Ebitda-2.31
Forecast
1Y Price Target
$32.40Price Target Upside125.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first oral FGFR3 therapy could reshape treatment if modest complete response and strong tolerability hold in the Phase 2 readout and beyond.
Product DevelopmentTYRA-300 could be favored over alternative options in NMIBC due to its oral route of administration, offering greater convenience and quality of life.
Bears Say
Market CompetitionIn NMIBC, dabogratinib could be the first oral therapy for FGFR3+ intermediate-risk NMIBC, with initial Phase 2 data expected, which could offer a massive convenience advantage over repeated intravesical catheterizations.
Product CompetitionTYRA-300 could achieve best-in-class efficacy at lower doses, given higher selectivity vs. pan-FGFR inhibitors.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $6.42 and its highest was $29.60 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $720.58M.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Oct 30, 2025 which is in 15 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on Aug 14, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.529 by $0.059.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.5.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 53,297,140 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.529. Following the earnings report the stock price went up 0.28%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
Tyra Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.40 (125.63% Upside)
$32.40 (125.63% Upside)
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 27.1%
Last 30 Days ▲ 27.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.55%
12-Months-Change
Fundamentals
Return on Equity
-31.21%
Trailing 12-Months
Asset Growth
-18.08%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$32.40
▲(125.63% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
50.21% Insiders
6.99% Mutual Funds
6.82% Other Institutional Investors
30.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---